We are on a mission to address the most challenging and unaddressed diseases impacting humankind.
ABOUT
PulmoSIM Therapeutics is the pharmaceutical subsidiary of VeriSIM Life, developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. Our immediate focus is to address the unmet needs in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) by targeting the underlying biology to alleviate the need for combination therapies.
We leverage BIOiSIM, a first-in-class artificial intelligence bio-simulation platform developed by VeriSIM Life, to accelerate our drug development by bridging the translational gap between preclinical and clinical phases.
PIPELINE
PulmoSIM Therapeutics’ pipeline includes 2 drug assets.
PT001 is a U.S. Food & Drug Administration designated Orphan Drug and has successfully completed preclinical study. PT001 has demonstrated positive efficacy with key disease-reversal data for the treatment of PAH. The monotherapy differs significantly from current PAH combination therapies by targeting the disease’s underlying biology. We are working hand-in-hand with a world-class strategic advisory board and clinical and manufacturing partners to rapidly transition the program to clinical studies.
PT002 is undergoing advanced preclinical study for the treatment of IPF.
Dr. Jo Varshney DVM, Ph.D.
CEO & Founder
Dr. Vivek Gupta, Ph.D.
Scientific Founder
Dr. Eva S. Nozik, MD
Strategic Advisor
Dr. Samir Mitragotri, Ph.D.
Strategic Advisor
Dr. Hugh Smyth, Ph.D.
Strategic Advisor
TEAM & ADVISORY BOARD
PRESS & NEWS
